Long-term Follow-Up of CA209-004: A Phase I Dose-Escalation Study of Combined Nivolumab (NIVO) and Ipilimumab (IPI) in Patients with Advanced Melanoma.
Journal of Clinical Oncology（2019）
Key words
Melanoma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined